Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?

Renato Zambello, Antonella Teramo, Cristina Gattazzo, Gianpietro Semenzato, Renato Zambello, Antonella Teramo, Cristina Gattazzo, Gianpietro Semenzato

Abstract

Mature Large Granular lymphocytes (LGL) disorders include a spectrum of conditions, ranging from polyclonal to clonal indolent and/or overt leukemic LGL proliferations. Most cases are represented by clonal expansions of TCRα/β+ LGL displaying a CD8+ phenotype with expression of cytotoxic T-cell antigens (CD57, CD16, TIA-1, perforin and granzyme B). Proliferations of CD3-CD16+ NK cells with a restricted patter of NK receptors are less common, usually comprising 15% of the cases. Main features are cytopenias, splenomegaly and autoimmune phenomena. Morphology, immunophenotyping and molecular analyses are crucial to establish a correct diagnosis of disease. According to the 2008 WHO classification, two separate entities account for the majority of cases, T-LGL leukemia and Chronic Lymphoproliferative Disease of NK cell (this latter still provisional). Although these disorders are characterized by the expansion of different cells types i.e. T and NK cells, with specific genetic features and abnormalities, compelling evidence supports the hypothesis that a common pathogenic mechanism would be involved in both disorders. As a matter of fact, a foreign antigen driven clonal selection is considered the initial step in the mechanism ultimately leading to generation of both conditions. In this chapter we will discuss recent advances on the pathogenesis of chronic T and NK disorders of granular lymphocytes, challenging the current WHO classification on the opportunity to separate T and NK disorders, which are likely to represent two sides of the same coin.

Keywords: CLPD-NK; CTL; NK cells; T-LGL leukemia.

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
See text for more details. Abbreviations. PB = peripheral blood; LGL = large granular lymphocytes; TCR = T cell receptor; KIRs = Killer Ig-like receptors.

References

    1. Semenzato G, Pandolfi F, Chisesi T, De Rossi G, Pizzolo G, Zambello R, et al. The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer 1987;60:2971-2978
    1. Loughran TP., Jr Clonal diseases of large granular lymphocytes. Blood 1993;82:1-14
    1. Oshimi K, Yamada O, Kaneko T, Nishinarita S, Iizuka Y, Urabe A, Inamori T, Asano S, Takahashi S, Hattori M, et al. Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders. Leukemia 1993;7(6):782-788
    1. Chan WC, Foucar KM, Morice WG, Catovsky D. T-cell large granular lymphocytic leukaemia. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008. p.272-273
    1. Villamor N, Morice WG, Chan WC, Foucar K. Chronic lymphoproliferative disorders of NK cells. Swerdlow SH, Campo E, Harris NL, Jaffe EJ, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008:274-275
    1. Pandolfi F, Loughran TP, Jr, Starkebaum G, Chisesi T, Barbui T, Chan WC, Brouet JC, De Rossi G, McKenna RW, Salsano F, et al. Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer 1990;65(2):341-348
    1. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood 1997;89:256-260
    1. Lamy T, Loughran TP., Jr How I treat LGL leukemia. Blood 2011; 117: 2764-2774
    1. Morice WG, Kurtin PJ, Tefferi A, Hanson CA. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood 2002;99:268-274
    1. Baesso I, Pavan L, Boscaro E, Miorin M, Facco M, Trentin L, Agostini C, Zambello R, Semenzato G. T-cell type lymphoproliferative disease of granular lymphocytes (LDGL) is equipped with a phenotypic pattern typical of effector cytotoxic cells. Leuk Res 2007;31:371-377
    1. Bourgault-Rouxel AS Loughran TP Jr Zambello R Epling-Burnette PK Semenzato G Donadieu J Amiot L Fest T Lamy T. Clinical spectrum of gammadelta+ T cell LGL leukemia: analysis of 20 cases. Leuk Res 2008;32:45-48
    1. Angelini DF, Zambello R, Galandrini R, Diamantini A, Placido R, Micucci F, Poccia F, Semenzato G, Borsellino G, Santoni A, Battistini L. NKG2A inhibits NKG2C effector functions of γδ T cells: implications in health and disease. J Leukoc Biol 2011;89:75-84
    1. Lima M, Almeida J, Santos AH, dos Anjos Teixeira M, Alguero MC, Queirós ML, Balanzategui A, Justiça B, Gonzalez M, San Miguel JF, Orfão A. Immunophenotypic analysis of the TCR-Vbeta repertoire in 98 persistent expansions of CD3(+)/TCR-alphabeta(+) large granular lymphocytes: utility in assessing clonality and insights into the pathogenesis of the disease. Am J Pathol 2001;159:1861-1868
    1. Beck RC, Stahl S, O’ Keefe CL, Maciejewski JP, Theil KS, Hsi ED. Detection of mature T-cell leukemias by flow cytometry using anti-T-cell receptor V beta antibodies. Am J Clin Pathol 2003;120:785-794
    1. Zambello R, Facco M, Trentin L, Sancetta R, Tassinari C, Perin A, Milani A, Pizzolo G, Rodeghiero F, Agostini C, Meazza R, Ferrini S, Semenzato G. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood 1997;89:201-211
    1. Zambello R, Falco M, Della Chiesa M, Trentin L, Carollo D, Castriconi R, Cannas G, Carlomagno S, Cabrelle A, Lamy T, Agostini C, Moretta A, Semenzato G, Vitale M. Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative disease of granular lymphocytes. Blood 2003;102:1797-1805
    1. Epling-Burnette PK, Painter JS, Chaurasia P, Bai F, Wei S, Djeu JY, Loughran TP., Jr Dysregulation of NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood 2004;103:3431-3439
    1. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepistö M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP, Jr, Heckman CA, Maciejewski JP, Mustjoki S. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366:1905-1913
    1. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, Olson T, Przychodzen B, Afable M, Gomez-Segui I, Guinta K, Durkin L, Hsi ED, McGraw K, Zhang D, Wlodarski MW, Porkka K, Sekeres MA, List A, Mustjoki S, Loughran TP, Maciejewski JP. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T cell large granular lymphocyte leukemia. Blood 2012;120:3048-3057
    1. Rajala HL, Eldfors S, Kuusanmäki H, van Adrichem AJ, Olson T, Lagström S, Andersson EI, Jerez A, Clemente MJ, Yan Y, Zhang D, Awwad A, Ellonen P, Kallioniemi O, Wennerberg K, Porkka K, Maciejewski JP, Loughran TP, Jr, Heckman C, Mustjoki S. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013;121:4541-4550
    1. Zambello R, Semenzato G. Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica 2009;94:1341-1345
    1. Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 1994;84:1620-1627
    1. Lamy T, Bauer FA, Liu JH, Li YX, Pillemer E, Shahidi H, Gregory SA, Zambello R, Marcolongo R, Semenzato G, Loughran TP. Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice. Br J Haematol 2000;108:717-723
    1. Semenzato G, Marino F, Zambello R. State of the art in natural killer cell malignancies. Int J Lab Hematol 2012;34:117-128
    1. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-1405
    1. Kawa-Ha K, Ishihara S, Ninomiya T, Yumura-Yagi K, Hara J, Murayama F, Tawa A, Hirai K. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest 1989;84:51-55
    1. Loughran TP., Jr Results of a prospective multicenter phase II study of initial treatment with methotrexate in LGL leukemia (ECOG protocol E5998) [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116(21):2595
    1. Gabor EP, Mishalani S, Lee S. Rapid response to cyclosporine therapy and sustained remission in large granular lymphocyte leukemia. Blood 1996;87:1199-1200
    1. Osuji N, Matutes E, Tjonnfjord G, Grech H, Del Giudice I, Wotherspoon A, Swansbury JG, Catovsky D. T-cell large granular lymphocyte leukemia: a report on the treatment of 29 patients and a review of the literature. Cancer 2006;107:570-578
    1. Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, Teramura M, Karasawa M, Arai A, Yonemura Y, Nakao S, Urabe A, Omine M, Ozawa K; PRCA Collaborative Study Group. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 2008;93(10):1555-1559
    1. Subbiah V, Viny AD, Rosenblatt S, Pohlman B, Lichtin A, Maciejewski JP. Outcomes of splenectomy in T-cell largegranular lymphocyte leukemia with splenomegaly and cytopenias. Exp Hematol 2008;36:1078.
    1. Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, Zou J, Painter JS, Edwards TD, Moscinski L, Yoder JA, Djeu JY, Sebti S, Loughran TP, Jr, Wei S. Clinical improvementby farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood 2008;112:4694-4698
    1. Garban F, Carras S, Drillat P, Jacob MC, Fabre B, Callanan M, Courby S, Makowski C, Cahn JY, Gressin R. Extracorporeal photopheresisas a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia. Ann Oncol 2012;23:2396-2390
    1. Shen L, Au WY, Guo T, Wong KY, Wong ML, Tsuchiyama J, Yuen PW, Kwong YL, Liang RH, Srivastava G. Proteasome inhibitor bortezomib-induced apoptosis in natural killer(NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation. Blood 2007;110:469-470
    1. Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol 2007;25:171-192
    1. Epling-Burnette PK, Loughran TP., Jr Survival signals in leukemic large granular lymphocytes. Semin Hematol 2003;40:213-220
    1. Zambello R, Trentin L, Facco M, Cerutti A, Sancetta R, Milani A, Raimondi R, Tassinari C, Agostini C, Semenzato G. Analysis of the T cell receptor in the lymphoproliferative disease of granular lymphocytes: superantigen activation of clonal CD3-granular lymphocytes. Cancer Res 1995;55:6140-6145
    1. Wlodarski MW, Nearman Z, Jankowska A, Babel N, Powers J, Leahy P, Volk HD, Maciejewski JP. Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia. J Leukoc Biol 2008;83:589-601
    1. Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK, Albert R, Loughran TP., Jr Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A 2008;105:16308-16313
    1. Zhang D, Loughran TP., Jr Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematology. Am Soc Hematol Educ Program 2012; pag.652-659
    1. Zambello R, Berno T, Cannas G, Baesso I, Binotto G, Bonoldi E, Bevilacqua P, Miorin M, Facco M, Trentin L, Agostini C, Semenzato G. Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL). Blood 2003;102:1797-1805
    1. Kawa-Ha K, Ishihara S, Ninomiya T, Yumura-Yagi K, Hara J, Murayama F, Tawa A, Hirai K. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest 1989;84:51-55
    1. Zambello R, Loughran TP, Jr, Trentin L, Pontisso P, Battistella L, Raimondi R, Facco M, Sancetta R, Agostini C, Pizzolo G, et al. Serologic and molecular evidence for a possible pathogenetic role of viral infection in CD3-negative natural killer-type lymphoproliferative disease of granular lymphocytes. Leukemia 1995;9(7):1207-1211
    1. Hart DN, Baker BW, Inglis MJ, Nimmo JC, Starling GC, Deacon E, Rowe M, Beard ME. Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood 1992;79:2116-2123
    1. Loughran TP, Jr, Hadlock KG, Yang Q, Perzova R, Zambello R, Semenzato G, Foung SK, Poiesz BJ. Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3- (natural killer) lymphoproliferative disease of granular lymphocytes. Blood 1997;90:1977-1981
    1. Sokol L, Agrawal D, Loughran TP., Jr Characterization of HTLV envelope seroreactivity in large granular lymphocyte leukemia. Leuk Res 2005;29:381-387
    1. Nearman ZP, Wlodarski M, Jankowska AM, Howe E, Narvaez Y, Ball E, Maciejewski JP. Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol 2007;136:237-248
    1. Teramo A, Gattazzo C, Passeri F, Lico A, Tasca G, Cabrelle A, Martini V, Frezzato F, Trimarco V, Ave E, Boscaro E, Piazza F, Facco M, Trentin L, Semenzato G, Zambello R. Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood 2013;121:3843-3854
    1. Yang J, Epling-Burnette PK, Painter JS, Zou J, Bai F, Wei S, Loughran TP., Jr Antigen activation and impaired Fas-induced death inducing signaling complex formation in T-large granular lymphocyte leukemia. Blood 2008;111:1610-1616
    1. Clemente MJ, Wlodarski MW, Makishima H, Viny AD, Bretschneider I, Shaik M, Bejanyan N, Lichtin AE, Hsi ED, Paquette RL, Loughran TP, Jr, Maciejewski JP. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood 2011;118:4384-4393 Erratum in: Blood 2012;120:1963. His, Eric D [corrected to Hsi, Eric D]
    1. Roullet MR, Cornfield DB. Large natural killer cell lymphoma arising from an indolent natural killer cell large granular lymphocyte proliferation. Arch Pathol Lab Med 2006;130:1712-1714
    1. Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000;95:3765-3770
    1. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000;19:2496-2504
    1. Eriksen KW, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C, Nissen MH, Röpke C, Wasik MA, Odum N. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 2001;15:787-793
    1. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TP., Jr Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001;107:351-362
    1. Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia 2012Dec 4, “in press”
    1. Sekiguchi N, Matsuda K, Momose K, Makishima H, Ito T, Ishida F. STAT3 gene mutations and the association with pure red cell aplasia in large granular lymphocyte leukemia. Blood (ASH Annual Meeting Abstracts), Nov2012;120:2668

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir